PDK1 and melanoma: As inhibition, silencing or gene ablation of PDK1 in experimental models have highlighted its suitability as a potential therapeutic target in breast [15], pancreatic cancers [18], and melanoma [19], understanding the precise mechanics of how PDK1 drives lung cancer development is of significant interest.